✦ LIBER ✦

Cholecystokinin peptides and receptor binding in Alzheimer's disease

✍ Scribed by C. Löfberg; J. Harro; C. -G. Gottfries; L. Oreland

Publisher: Springer
Year: 1996
Tongue: English
Weight: 686 KB
Volume: 103
Category: Article
ISSN: 1435-1463
DOI: 10.1007/bf01273363

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Loss of high-affinity agonist receptor b

Loss of high-affinity agonist receptor binding in Alzheimer's disease

✍ Jacques De Keyser 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB

Siglec receptors and hiding plaques in A

Siglec receptors and hiding plaques in Alzheimer's disease

✍ Antero Salminen; Kai Kaarniranta 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 162 KB

ChemInform Abstract: Modeling Copper Bin

ChemInform Abstract: Modeling Copper Binding to the Amyloid-β Peptide in Alzheimer′s Disease.

✍ V. Chandana Epa; Victor A. Streltsov; Joseph N. Varghese 📂 Article 📅 2010 🏛 John Wiley and Sons ⚖ 20 KB 👁 1 views

## Abstract Review: 44 refs.

Does apolipoprotein E (Apo-E) genotype i

Does apolipoprotein E (Apo-E) genotype influence nicotinic receptor binding in Alzheimer's disease

✍ R. T. Reid; M. N. Sabbagh; L. J. Thal 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 102 KB

The amyloid-β peptide and its role in Al

The amyloid-β peptide and its role in Alzheimer's disease

✍ Andrew B. Clippingdale; John D. Wade; Colin J. Barrow 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 334 KB

## Abstract Amyloid formation plays a central role in the cause and progression of Alzheimer's disease. The major component of this amyloid is the amyloid‐β (Aβ) peptide, which is currently the subject of intense study. This review discusses some recent studies in the area of Aβ synthesis, purifica

Alzheimer'S disease: Monoamines and spip

Alzheimer'S disease: Monoamines and spiperone binding reduced in nucleus basalis

✍ D. Larry Sparks; William R. Markesbery; Dr John T. Slevin 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 338 KB 👁 1 views

This research was carried out during the tenure of a postdoctoral fellowship from the Muscular Dystrophy Association awarded to Dr Argov. We thank Dr N. R. M. Buist for his ongoing interest in this case and the support of his Muscular Dystrophy Association grant.